Logo

GANX

Gain Therapeutics, Inc.

GANX

Gain Therapeutics, Inc. • NASDAQ
$3.50 ▲ 11.46% (+0.36)
Market Cap $126.33 M
52w High $3.65
52w Low $1.41
Dividend Yield 0%
P/E -5.74
Volume 1.16M
Outstanding Shares 36.10M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $4.763M ▲ $-5.284M ▲ 0% $-0.151 ▲ $-4.712M ▲
Q2-2025 $0 $2.367M ▲ $-5.809M ▼ 0% $-0.19 ▼ $-5.085M ▼
Q1-2025 $0 $2.146M ▼ $-4.53M ▼ 0% $-0.16 ▼ $-4.364M ▼
Q4-2024 $0 $3.31M ▼ $-3.768M ▲ 0% $-0.14 ▲ $-3.242M ▲
Q3-2024 $0 $4.184M $-4.486M 0% $-0.17 $-4.449M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $8.807M ▲ $10.972M ▲ $5.062M ▼ $5.909M ▲
Q2-2025 $6.694M ▼ $9.834M ▼ $6.138M ▲ $3.696M ▼
Q1-2025 $9.07M ▼ $11.624M ▼ $5.844M ▲ $5.78M ▼
Q4-2024 $10.386M ▼ $12.124M ▼ $4.784M ▼ $7.34M ▼
Q3-2024 $12.05M $14.366M $5.456M $8.909M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-5.284M ▲ $-4.926M ▲ $0 $7.033M ▲ $2.113M ▲ $-4.926M ▲
Q2-2025 $-5.809M ▼ $-5.099M ▼ $0 $2.467M ▲ $-2.372M ▼ $-5.099M ▼
Q1-2025 $-4.53M ▼ $-3.822M ▼ $0 ▲ $2.397M ▲ $-1.315M ▲ $-3.822M ▼
Q4-2024 $-3.768M ▲ $-3.455M ▲ $-43.447K ▼ $2.313M ▲ $-1.666M ▲ $-3.456M ▲
Q3-2024 $-4.486M $-6.076M $-1 $808.678K $-4.885M $-6.076M

Five-Year Company Overview

Income Statement

Income Statement Gain Therapeutics is still a pure research‑stage biotech, with no product sales yet. Its expenses are driven mainly by R&D and general corporate costs, which consistently lead to annual losses. Those losses have been fairly steady over the last few years, reflecting a disciplined but ongoing investment in clinical and platform development rather than rapid cost escalation. Earnings per share have been negative each year, which is typical for an early‑stage biotech that has not yet commercialized a drug.

Balance Sheet

Balance Sheet The company runs with a very lean balance sheet, holding a small base of assets largely made up of cash and equivalents. It carries no financial debt, which reduces interest burden and default risk but also means it must rely on equity raises or partnerships to fund growth. Shareholders’ equity has gradually declined as accumulated losses have outpaced new capital coming in, which is common for small, pre‑revenue biotechs. Overall, financial flexibility is limited and closely tied to the company’s ability to access capital markets or strategic funding.

Cash Flow

Cash Flow Cash flow is clearly negative from operations, reflecting ongoing spending on research, clinical trials, and corporate overhead without any offsetting revenue. Capital spending is minimal, suggesting the company is not tied up in heavy physical infrastructure and is mainly investing in people, trials, and technology. Free cash flow is consistently negative, which means the business depends on external funding to sustain its pipeline. The cash burn appears steady rather than explosive, but given the small cash base, funding runway and future raises are key risks to watch.

Competitive Edge

Competitive Edge Gain’s competitive edge centers on its Magellan platform, which uses advanced computational tools to find novel allosteric sites on proteins that are hard to drug with traditional methods. This specialization in allosteric modulation, supported by proprietary algorithms and know‑how, gives it a differentiated scientific niche versus more generalist biotech platforms. Its lead focus on GBA1‑related pathways in Parkinson’s and rare disorders could offer first‑in‑class or best‑in‑class potential if the data hold up. However, it operates in a highly competitive field with many larger, better‑funded players in neurology and rare diseases, and it is still heavily reliant on the success of a small number of early‑stage programs. The partnership in oncology provides some external validation, but the company’s negotiating power and long‑term moat will depend on future clinical results.

Innovation and R&D

Innovation and R&D Innovation is the core of Gain’s story: the Magellan platform is designed to systematically discover new druggable spots on proteins that were previously considered out of reach, especially for brain and lysosomal diseases. Its lead candidate, GT‑02287, targets a key enzyme involved in GBA1‑linked Parkinson’s and related conditions, with early human data suggesting target engagement and tolerability. Beyond this, the company is building a portfolio in rare lysosomal storage diseases and has extended its discovery capabilities into oncology via collaboration. R&D intensity is high, as expected, and progress will be judged by the ability to move programs from early discovery into later‑stage trials. The main risk is classic for biotech: scientific and clinical uncertainty, plus a pipeline that is still relatively concentrated in one main mechanism.

Summary

Gain Therapeutics is an early‑stage, platform‑driven biotech with no revenue yet and a clear focus on high‑risk, high‑reward innovation in neurology and rare diseases. Financially, it operates with a small asset base, no debt, and recurring losses funded by its limited cash and periodic external capital, making ongoing access to funding a central concern. Its long‑term potential rests on the Magellan discovery platform and the success of GT‑02287 and related programs, which could open new treatment options for difficult diseases if clinical data continue to be supportive. At the same time, the company faces the usual biotech challenges: trial risk, regulatory uncertainty, strong competition, and a narrow pipeline focus. Overall, this is a classic clinical‑stage biotech profile—scientifically ambitious but financially and operationally dependent on future trial outcomes and financing events.

NEWS

November 20, 2025 · 7:00 AM UTC

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025

Read more

November 12, 2025 · 7:00 AM UTC

Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update

Read more

October 30, 2025 · 7:00 AM UTC

Gain Therapeutics to Present at Neuroscience 2025

Read more

October 16, 2025 · 7:00 AM UTC

Gain Therapeutics to Attend the 2025 Maxim Growth Summit

Read more

October 9, 2025 · 7:00 AM UTC

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease

Read more